CYP2C9 and CYP2C19 genetic polymorphisms: Frequencies in the south Indian population

Fundamental and Clinical Pharmacology

Volumn 19, Issue 1, 2005, Pages 101-105

  Jose, Rosemary ^a   Chandrasekaran, Adithan ^a   Sam, Soya Sisy ^a   Gerard, Nathalie ^b   Chanolean, Shashindran ^a   Abraham, Benny K ^c   Satyanarayanamoorthy, K ^d   Peter, Anitha ^c   Rajagopal, Krishnamoorthy ^b  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c MAHATMA GANDHI UNIVERSITY   (India)

^d Rangaraya Med Coll   (India)

Author keywords

Allele; CYP2C19; CYP2C9; PCR RFLP; Polymorphism; South India

Indexed keywords

ADULT; ALLELE; ARTICLE; CAUCASIAN; CHINESE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYP2C19 1 GENE; CYP2C19 2 GENE; CYP2C19 3 GENE; CYP2C19 GENE; CYP2C9 1 GENE; CYP2C9 2 GENE; CYP2C9 3 GENE; CYP2C9 GENE; DATA ANALYSIS; DRUG METABOLISM; FEMALE; FISHER EXACT TEST; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INDIA; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION DISTRIBUTION; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; HUMANS; INDIA; MALE; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 13444256260     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2004.00307.x     Document Type: Article

References (15)

1. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics (2002) 12 251-263.
2. Daly A.K. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fund. Clin. Pharmacol. (2003) 17 27-41.
3. Aynacioglu A.S., Brockmoller J., Bauer S. et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. (1999) 48 409-415.
4. Tanigawara Y., Aoyama N., Kita T. et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin. Pharmacol. Ther. (1999) 66 528-534.
5. Xie H.G., Prasad H.C., Kim R.B., Stein C.M. CVP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. (2002) 54 1257-1270.
6. Xie H.G., Stein C.M., Kim R.B., Wilkinson G.R., Flockhart D.A., Wood A.J. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics (1999) 9 539-549.
7. Xie H.G. Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population. Life Sci. (2000) 66 175-181.
8. Kaneko A., Lum J.K., Yaviong J. et al. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and Pacific islands. Pharmacogenetics (1999) 9 581-590.
9. Adithan C., Gerard N., Vasu S., Balakrishnan R., Shashindran C.H., Krishnamoorthy R. Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur. J. Clin. Pharmacol. (2003) 59 707-709.
10. Adithan C., Gerard N., Vasu S., Rosemary J., Shashindran C.H., Krishnamoorthy R. Allele and genotype frequency of CYP2C19 in a Tamilian population. Br. J. Clin. Pharmacol. (2003) 56 331-333.
11. Sanger F., Nicklen., Coulsen A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA (1977) 74 5463-5467.
12. Lamba J.K., Dhiman R.K., Kohli K.K. CYP2C19 genetic mutations in north Indians. Clin. Pharmacol. Ther. (2000) 68 328-335.
13. Setiabudy R., Kusaka M., Chiba K., Darmansjah I., Ishizaki T. Metabolic disposition of proguanil in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Indonesian population. Br. J. Clin. Pharmacol. (1995) 39 297-303.
14. Bramness J.G., Skurtveit S., Fauske L. et al. Association between blood carisoprodol: meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics (2003) 13 383-388.
15. Skjelbo E., Mutabingwa T.K., Bygbjerg I., Nielsen K.K., Gram L.F., Broosen K. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin. Pharmacol. Ther. (1996) 59 304-311.